N-叔丁氧羰基-L-谷氨酸 1-甲酯 | 72086-72-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-叔丁氧羰基-L-谷氨酸 1-甲酯
• 中文别名: N-叔丁氧羰基-L-谷氨酸1-甲酯
• 英文名称: N-tert-butoxycarbonylglutamic acid methyl ester
• 英文别名: Boc-Glu-OMe；(S)-4-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid；Boc-Glu(OH)-OMe；(4S)-4-(tert-butoxycarbonylamino)-5-methoxy-5-oxo-pentanoic acid；Boc-L-Glu-OMe；N-(tert-butoxycarbonyl)-L-glutamic acid α-methyl ester；Boc-L-glutamic acid α-methyl ester；L-Boc-Glu-OCH3；(4S)-5-methoxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid
• CAS: 72086-72-7
• 化学式: C₁₁H₁₉NO₆
• 分子量: 261.275
• InChiKey: ZAYAFKXUQMTLPL-ZETCQYMHSA-N

物化性质

• 熔点：
  119-123℃
• 沸点：
  428.4±40.0 °C(Predicted)
• 密度：
  1.182±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-Glu-OMe
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-Glu-OMe
CAS number: 72086-72-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H19NO6
Molecular weight: 261.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

N-叔丁氧羰基-L-谷氨酸1-甲酯是一种有机中间体，可用于制备(3R)或(3S)-氨基-哌啶-2-酮。该化合物是合成Sulphostin (DPP-IV)以及具有抑制海拉细胞毒性的(3S,9S)-Ciliatamides C等重要有机片段的关键中间体。

用途

N-叔丁氧羰基-L-谷氨酸1-甲酯是一种羧酸酯类衍生物，可用作有机合成的中间体。

反应信息

• 作为反应物：
  描述：

  N-叔丁氧羰基-L-谷氨酸 1-甲酯 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.5h， 生成 methyl (S)-2-tert-butoxycarbonylamino-5-hydroxynorvalinate
  参考文献：
  名称：

  非谷氨酸型吡咯并[2,3-d]嘧啶类抗叶酸药。三，N（Ω）掩蔽鸟氨酸类似物的合成和生物学性质。

  摘要：

  N- [4- [3-（2,4-二氨基-7H-吡咯并[2,3-d]嘧啶-5-基）丙基]苯甲酰基] -Lg谷氨酸的谷氨酸部分（1b，TNP-351 ）和相关化合物（1a）替换为各种N（ω）-酰基-，磺酰基-，氨基甲酰基-和芳基-2，ω-二氨基链烷酸，以及所得产物的抑制作用（9、11、14分别在二氢叶酸还原酶（DHFR）上检测了18、21、23、25、30、36），小鼠纤维肉瘤Meth A细胞和耐甲氨蝶呤的人CCRF-CEM细胞的生长。通过偶合吡咯并[2,3-d]嘧啶羧酸（7a，b）和N（ω）-邻苯二甲酰基2，ω-二氨基链烷酸甲酯（6a-）有效地合成了被半邻苯二甲酰基化的化合物（9a-f） c）和随后的水解。其他N（ω）-酰基和磺酰基-鸟氨酸类似物（21，23，25）通过酰化衍生自叔丁氧基羰基鸟氨酸类似物（17a，b）的游离氨基中间体（19a，b）而合成。游离鸟氨酸类似物（18）不能强烈抑制Meth

  DOI：

  10.1248/cpb.48.1270
• 作为产物：
  描述：

  L-谷氨酸 在 palladium on activated charcoal 硫酸 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-叔丁氧羰基-L-谷氨酸 1-甲酯
  参考文献：
  名称：

  设计和合成环状伪二肽的所有非对映异构体，以模拟环状CXCR4五肽拮抗剂。

  摘要：

  2,5-双[（3-胍基）丙基] -1- [3-（4-羟苯基）丙酰基] -7-（2-萘乙酰基）-1,4,7-三氮杂环十一烷基-9-en的四种非对映异构体-3-one（-）和2,5-双[（3-胍基）丙基] -1-（4-羟基苯基乙酰基）-7-（2-萘基乙酰基）-1,4,7-三氮杂环十一烷基-9-en通过发散的方法从I-和D-谷氨酸合成-3-一个（-）。通过线性双（烯丙基胺）的闭环复分解反应制得11元环核，并使用双（Boc）胍通过同时的两次Mitsunobu反应引入胍基官能团。设计这些化合物以模拟环状五肽FC131（c [Gly-D-Tyr-Arg-Arg-Nal]）。

  DOI：

  10.1039/b702649h

文献信息

• 一种蛋白质化学交联剂及其制备方法与应用
  申请人：北京大学

  公开号：CN107652316B

  公开（公告）日：2020-01-03

  本发明涉及一种蛋白质化学交联剂，其结构如通式I所示；本发明同时涉及所述蛋白质化学交联剂的制备方法。本发明提供的多功能交联剂交联效率和稳定性都很好，尤其是基于三甲基硅基重氮甲基功能团类型的交联剂，对天冬氨酸和谷氨酸的侧链羧基以及蛋白质的碳端羧基的交联效率很高，是首例无需加入缩合剂活化的基于含有羧基的氨基酸残基选择性的交联剂。本发明通过对N‑(Boc)谷氨酸甲酯以及对含多种氨基酸的多肽的交联反应证明所述交联剂了对含有羧酸氨基酸残基有很高的交联效率及选择性，其与九种模式蛋白质和一种含有八种蛋白的混合物的交联反应证明了该类交联剂与含有羧基的氨基酸残基的简单纯蛋白体以及复杂的蛋白体系都具有很高的交联效率。R1‑X‑R2‑‑I。
• Copper‐Promoted O‐Arylation of the Phenol Side Chain of Tyrosine Using Triarylbismuthines
  作者：Adrien Le Roch、Martin Hébert、Alexandre Gagnon

  DOI：10.1002/ejoc.202000790

  日期：2020.9.7

  for the O‐arylation of the side chain of tyrosine using triarylbismuth reagents is reported. The reaction is performed in dichloromethane under oxygen at 50 °C in the presence of pyridine, is promoted by copper diacetate, shows excellent scope and functional group tolerance, and retains the integrity of the chiral center. The reactivity of other amino acids possessing a nucleophilic side chain under these

  报道了使用三芳基铋试剂对酪氨酸侧链进行O-芳基化的方法。该反应在吡啶存在下于氧气中于50°C的氧气中于二氯甲烷中进行，由二乙酸铜促进，显示出极好的范围和官能团耐受性，并保留了手性中心的完整性。研究了在这些条件下具有亲核侧链的其他氨基酸的反应性。可以实现含酪氨酸的二肽和三肽的O-酰化。
• [EN] INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2021206876A1

  公开（公告）日：2021-10-14

  Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.

  公式（I）化合物及抑制生物样本或患者中病毒复制、减少生物样本或患者中病毒数量、以及治疗患者病毒感染的方法，包括向所述生物样本或患者投与由公式（I）表示的化合物、表A或B中的化合物或其药用可接受盐的有效量。
• Novel diarylalkene derivatives and novel diarylalkane derivatives
  申请人：AJINOMOTO CO., INC.

  公开号：US20040167118A1

  公开（公告）日：2004-08-26

  The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: 1 wherein, A represents CH═CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V—W represents C═C, etc., n represents 0 to 3, Y1 represents O etc., B represents —(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents —CO—, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, —COR18a, —COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

  该发明涉及以下一般式（1）或其类似物所代表的化合物，该化合物选择性地抑制N型钙通道或其类似物，并涉及将该一般式（1）或其类似物所代表的化合物用于需要此类治疗的患者的治疗方法： 1 其中，A代表CH═CH等，a、b、c和d代表CH等，R1、R2、R3、R4、R5和R6代表H等，V—W代表C═C等，n代表0至3，Y1代表O等，B代表—(CH2)vCHR21，其中v为0至3，R21代表H、较低的烷基基团或类似物等，G代表—CO—、共价键等，m为0至6，R7和R8代表H、较低的烷基基团、—COR18a、—COOR20，其中R18a和R20各自代表较低的烷基基团或类似物等。
• [EN] PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] DÉRIVÉS DE N5-MÉTHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE PEPTIDOMIMÉTIQUES, DÉRIVÉS DE TRIAZASPIRO[4.14]NONADÉCANE ET COMPOSÉS SIMILAIRES UTILISÉS EN TANT QU'INHIBITEURS DE RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2021188620A1

  公开（公告）日：2021-09-23

  Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).

  肽拟态N5-甲基-N2-(壬酰基-L-亮氨酰基)-L-谷氨酸衍生物，三唑螺[4.14]十九烷衍生物以及类似化合物用于抑制生物样本或患者中诺如病毒和冠状病毒的复制，用于减少生物样本或患者中诺如病毒或冠状病毒的数量，以及用于治疗患者中的诺如病毒和冠状病毒，包括向所述生物样本或患者施用由公式I或II表示的化合物的安全有效量，或其药用可接受盐。本描述公开了典型化合物的合成和特性，以及其药理数据（例如，第99页至第271页；例1至例3；化合物A1至A104和B1至B66；表A至表E）。